BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » news » Page 2

Oscine Therapeutics to Develop Stem Cell Therapies for CNS Disorders with Support from Sana Biotechnology

June 11, 2019 By Cade Hildreth (CEO) Leave a Comment

Oscine

OscineOscine Therapeutics is a newcomer to the stem cell sector, a private biotech company exploring mechanisms for treating neurodegenerative disorders through the use of replacing lost or damaged glia cells. The company is based the renowned research of Steve Goldman, M.D., Ph.D., co-director of the University of Rochester Medical Center (URMC) Center for Translational Neuromedicine.

The focus of Dr. Goldman’s research has been to manipulate the chemical signaling of pluripotent stem cell types, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPS cells), to create healthy glia cells. [Read more…]

Filed Under: Cell Therapy, Stem Cell News Tagged With: neurodegenerative, news, Oscine Therapeutics

Minerva Biotechnologies, Interview with CEO Dr. Cynthia Bamdad

June 4, 2019 By Cade Hildreth (CEO) 1 Comment

Minerva Biotechnologies

Minerva Biotechnologies is a regenerative medicine company specializing in stem cell therapeutics that is developing cancer immunotherapies to target 75% of solid tumors and to prevent cancer metastasis. I had the honor of interviewing Cynthia Bamdad, PhD, CEO of Minerva Biotechnologies.

In this interview, we discuss Minerva’s technology platform, product portfolio, IP strategy, and strategic goals. We also explore the significance of the company’s AlphaSTEM™ Culture System that is a simple method for inducing the naïve state in human stem cells. Enjoy. [Read more…]

Filed Under: Interviews, Stem Cells Tagged With: interview, Minerva Biotechnologies, news

ORIG3N, Producing Patient-Specific iPS Cells – Interview with Robin Smith, CEO

November 12, 2018 By Cade Hildreth (CEO) Leave a Comment

ORIG3N

ORIG3N ORIG3N, a biotechnology start-up headquartered in Boston, is attracting global attention for several reasons. First, it has created the world’s largest blood cell repository. ORIG3N is using these blood cells to produce patient-specific induced pluripotent stem cells (iPSCs), allowing the cells to be ever-renewing and giving rise to a living database of humanity known as LifeCapsule.

Second, the company has two other business segments, called LifeProfile and LifeSystems. These business units of ORIG3N help people to better understand the links between their genes and how their minds and bodies work.

Third, ORIG3N has identified HLA Superdonor matches for 90% of the U.S. population, positioning it to be custodians of this “first of a kind asset on planet earth.”

[Read more…]

Filed Under: Interviews, iPS Cells Tagged With: genetic testing, interview, iPSC, news, Orig3n

Cellerant Therapeutics Awarded 20th RMAT in U.S.

July 7, 2018 By Cade Hildreth (CEO) Leave a Comment

Cellerant RMAT

Cellerant Therapeutics RMATOn July 2nd, 2018, Cellerant Therapeutics was awarded a Regenerative Medicine Advanced Therapy (RMAT) designation for romyelocel-L (human myeloid progenitor cells) by the U.S. FDA. The treatment is used for the “prevention of serious bacterial and fungal infections in patients with de novo acute myeloid leukemia (AML) undergoing induction chemotherapy.”

Cellerant RMAT Designation

Romyelocel- is a universal, off-the-shelf cell therapy, because it does not require HLA matching between patient and donor. Neutropenia is a major side effect of myelosuppressive chemotherapies, including induction therapy. This can endanger patients by placing them at risk for life-threatening infections.

According to Ram Mandalam, President and CEO of Cellerant, “Receiving RMAT designation for romyelocel-L is an important milestone and recognition by the FDA of the potential of romyelocel-L to serve this unmet medical need.” [Read more…]

Filed Under: Cell Therapy, Stem Cell News Tagged With: news, RMAT

PolarityTE, Interview with Dr. Denver Lough, President and CEO

January 27, 2018 By Cade Hildreth (CEO) Leave a Comment

PolarityTE Denver Lough

PolarityTE

PolarityTE is an innovative company that has developed a platform to regenerate a variety of functionally polarized tissue substrates, such as skin, bone, muscle, cartilage, blood vessels, peripheral nerves, and more.  I had the honor of interviewing Dr. Denver Lough, Chairman, President, CEO, and CSO of PolarityTE. In this interview, we explore the origins of PolarityTE as a company. We also explore the company’s novel technology, 5-year vision, and future directions. Enjoy. [Read more…]

Filed Under: Interviews Tagged With: interview, news, PolarityTE, tissue engineering

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.